CERVOMED INC. - COMMON STOCK

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

31 يناير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Present at the 8th International Lewy Body Dementia Conference

29 يناير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

10 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

27 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Key Senior Leadership Appointments

13 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

12 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

08 نوفمبر 2024 09:55:32 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

07 نوفمبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

04 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

29 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

15 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

02 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

26 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

27 أغسطس 2024 08:30:00 بحسب Nasdaq GlobeNewswire

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

22 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

12 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

30 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

29 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference

17 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire